Expert panel evaluation of epidemiological evidence |
Low |
|
|
|
|
|
Expert panel evaluation of toxicological evidence |
Strong |
|
|
|
|
|
Probability of causation, % |
40–69 |
|
|
|
|
|
Percentile of exposure |
0–9 |
10–24 |
25–49 |
50–74 |
75–89 |
>90 |
Percentile assumed |
0 |
10 |
25 |
50 |
75 |
90 |
Urinary MBzP, ng/mL |
0 |
1.4 |
2.5 |
4.5 |
8.7 |
18 |
MBzP-exposed fecundity OR |
1.00 |
0.85 |
0.80 |
0.76 |
0.72 |
0.68 |
Urinary MBP, ng/mL |
0 |
8.9 |
14.9 |
24.5 |
41.4 |
68 |
MBP-exposed fecundity OR |
1.00 |
0.65 |
0.61 |
0.58 |
0.55 |
0.52 |
Rate of infertility across entire population of couples attributable to MBzP, % |
3.30 |
|
|
|
|
|
Rate of infertility across entire population of couples attributable to MBP, % |
7.15 |
|
|
|
|
|
Total rate of infertility across entire population attributable to MBP +/or MBzP (accounting for double counting), % |
9.38 |
|
|
|
|
|
Women ages 15–49 in consensual union, n |
59 527 000 |
|
|
|
|
|
Women ages 20–44 in consenual union not using contraception, n |
11 765 294 |
|
|
|
|
|
Attributable infertility cases seeking medical care, n |
618 000 |
|
|
|
|
|
Cost of ART attributable to phthalate exposure |
€4.71 billion |
|
|
|
|
|